{"id":904168,"date":"2025-11-03T10:02:07","date_gmt":"2025-11-03T15:02:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-secures-up-to-150-million-in-non-dilutive-financing-from-oxford-finance\/"},"modified":"2025-11-03T10:02:07","modified_gmt":"2025-11-03T15:02:07","slug":"kyverna-therapeutics-secures-up-to-150-million-in-non-dilutive-financing-from-oxford-finance","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-secures-up-to-150-million-in-non-dilutive-financing-from-oxford-finance\/","title":{"rendered":"Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance"},"content":{"rendered":"
\n

\n Initial funding of $25 million from the first of four tranches\u00a0<\/em>\n <\/p>\n

\n Facility strengthens Kyverna\u2019s financial flexibility, further supporting advancement of its late-stage indications in generalized myasthenia gravis (gMG) and stiff person syndrome (SPS), while also accelerating pre-launch activities<\/em>\n <\/p>\n

\n Topline data readout of registrational Phase 2 SPS trial now expected in early 2026; narrowed from previous guidance of first half 2026<\/em>\n <\/p>\n

EMERYVILLE, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) — Kyverna Therapeutics, Inc.\u00a0(Nasdaq: KYTX) (\u201cKyverna\u201d), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that, on October 31, 2025, it closed a loan facility with Oxford Finance LLC (“Oxford Finance”) for up to $150 million in non-dilutive capital. The Company will initially be drawing $25 million under the facility on November 3, 2025, with additional tranches available based on the achievement of key clinical and commercial milestones aligned with Kyverna\u2019s growth strategy and funding needs.<\/p>\n

\u201cWe are pleased to partner with Oxford Finance on a strategic, non-dilutive financing agreement with attractive terms that strengthen our financial flexibility,\u201d said Warner Biddle, Chief Executive Officer of Kyverna. \u201cThis facility further supports the rapid progress across our late-stage programs, including in myasthenia gravis, where we look forward to initiating enrollment in our Phase 3 registrational trial by the end of this year following positive interim Phase 2 trial data, and in stiff person syndrome, in which we are tracking ahead of schedule to report topline registrational results early next year.\u201d<\/p>\n

\u201cKyverna is uniquely positioned to potentially become the first company to deliver an approved CAR T-cell therapy for an autoimmune disease and we\u2019re proud to be partnering with this outstanding team to advance that mission,\u201d said Kirk Andrews, Managing Director of Oxford Finance. \u201cThis investment reflects Kyverna\u2019s continued strong execution on their strategy and the promising potential of KYV-101, as consistently demonstrated in treated patients across multiple autoimmune indications, including most recently in generalized myasthenia gravis.\u201d<\/p>\n

The $150 million loan facility includes an initial tranche of $40 million and two additional tranches totaling $60 million, subject to the satisfaction of certain terms and conditions of the loan and security agreement. A fourth tranche of $50 million may also be made available subject to Oxford Finance\u2019s discretion. Kyverna will be drawing $25 million from funds available from the first tranche on November 3, 2025. The facility matures on October 1, 2030.<\/p>\n

At the closing of the loan facility, Kyverna continues to expect to have cash runway into 2027, supporting its BLA filing for SPS and its MG Phase 3 trial, while also accelerating pre-launch activities.<\/p>\n

\n Anticipated Milestones<\/strong>\n <\/p>\n